Sonnet BioTherapeutics Says Phase 1 Trial of SON-1010 Shows Partial Tumor Response, Disease Stabilization

Sonnet BioTherapeutics表示SON-1010的第一阶段试验显示部分肿瘤反应，疾病稳定。

MT Newswires · 2024/12/09 22:28

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

登录免费看全文

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Sonnet BioTherapeutics Says Phase 1 Trial of SON-1010 Shows Partial Tumor Response, Disease Stabilization

Sonnet BioTherapeutics Says Phase 1 Trial of SON-1010 Shows Partial Tumor Response, Disease Stabilization

风险及免责提示

声明